Xenetic Biosciencesinc Nasdaqxbiois A Biopharmaceutical Company Focused On Progressing Xcarta Personalized Car T Platform Technology Engineered To Target Patient Specific Tumor Neoantigensthe Company Is Initially Advancing Cell Based Therapeutics Targeting The Unique B Cell Receptor On The Surface Of An Individual Patient S Malignant Tumor Cells For The Treatment Of B Cell Lymphomasxcart Has The Potential To Fuel A Robust Pipeline Of Therapeutic Assets Targeting High Value Oncology Indications Additionallyxenetic Is Leveraging Polyxena Cits Proprietary Drug Delivery Platformby Partnering With Biotechnology And Pharmaceutical Companiespolyxena C Has Demonstrated Its Ability To Improve The Half Life And Other Pharmacological Properties Of Next Generation Biologic Drugsthe Company Has An Exclusive License Agreement With Takeda Pharmaceuticals Coltdin The Field Of Coagulation Disorders And Expects To Earn Royalty Payments Under This Agreement
